ABSTRACT-Concomitant resistance to a second tumor implant was induced in both conventional and nude BALB/c mice by two non immunogenic syngeneic tumors of spontaneous origin, an epidermoid carcinoma and a lymphoid leukemia. In the secondary tumor, which was significantly inhibited by concomitant resistance, histologic examination revealed the presence of well-preserved tumor cells without any sign of necrosis and without any host cell infiltration, contrasting with classical immunologic rejection. Tumor cell proliferation as evaluated by the number of mitoses per high-power field was significantly inhibited in the secondary tumor as compared with the corresponding controls. No effect of concomitant resistance could be detected on primary tumor growth. -JNCI 1986; 76:1163-1175 
The phenomenon according to which a tumor-bearing host inhibits or retards the growth of a second implant of the same tumor carried out in a different site has been known as concomitant immunity since Bashford et al. (1) coined the term. This nomenclature implies an immunologic interpretation supported by experimental evidence for some tumor models (2-7) but remains questionable for others (8, 9) , the reason for which, in our opinion, the term concomitant resistance seems more appropriate. Such concomitant resistance has received little attention from most investigators despite the fact that it has been detected in association with human cancers (10, 11) and despite its possible relevance to the control of metastases (12, 13) .
In a previous paper (14) concomitant resistance was described in association with 3 mouse tumors of spontaneous origin and with another one induced by foreign body tumorigenesis, all 4 of which proved to lack detectable immunogenicity, as evaluated by several immunization assays. This concomitant resistance did not seem to be mediated by T-cells or macrophages; it affected not only secondary tumor grafts but also an actively growing tumor that had undergone partial excision, and it appeared to operate through a noncytotoxic mechanism. This paper extends these observations by means of histologic studies of both the primary and secondary implants of 2 non immunogenic murine tumors of spontaneous origin inducing concomitant resistance; to our knowledge, such a histologic approach has not been undertaken before. The questions asked were the following. 1) Was the growth inhibition of the second graft due to conventional cytotoxic rejection or to a cytostatic effect on tumor cell proliferation? 2) Was it associated with any host cell infiltration? 3) Was the primary tumor affected in any way by concomitant resistance? The term "cytostasis" was utilized to denote not only an absolute inhibition but also a retarding effect on cell proliferation.
MATERIALS AND METHODS
Animals.-BALB/c (H2-d) and AKR (H2_k) mice of both sexes, 2-4 months old, were used. They were raised in our colony and maintained on Cargill pellets and water ad libitum. Nude BALB/c mice were obtained from the Comisi6n Nacional de Energia At6mica, Argentina, and kept under relatively aseptic conditions. T -deficiency was assessed by humoral response to sheep erythrocytes and by graft vs. host reaction. Animals were age and sex matched within each experiment.
Test tumors.-The following 2 tumors were used to induce concomitant resistance.
CEI: CEI, as determined by differential staining techniques, arose spontaneously in a 12-month-old BALB/c female and is maintained by syngeneic sc serial passages. It was used between passages 8-17. It grows to a large size in situ, and at autopsy lung metastases are occasionally encountered. The number of sc injected viable tumor cells required to given an LD50 was 6-7XlOl! along the different passages. We have not been able to detect any degree of immunogenicity in CEI, using tumor implantation and excision as the immunization procedure in spite of its exhibiting a strong concomitant resistance (14) .
LB: LB as determined histologically, arose spontaneously in a 6-month-old BALB/c male and is maintained by sc serial passages in syngeneic mice. It was used between passages 69-114. It grows to a large size in situ; and, at autopsy, infiltration of lymph nodes, spleen, and liver can be detected. Its LD50 was approxi-mately 1,000 along the different passages. LB did not exhibit any degree of immunogenicity as evaluated by the several immunization procedures and by the Winn test but showed a strong concomitant resistance (14) .
Control tumors.-The following tumors were used as the control for immunologic rejection or positive Winn test.
1) CEI: This carcinoma (BALB/c origin) was transplanted in an allogeneic host (AKR mice).
2) MC-D: This fibrosarcoma arose in a 6-month-old BALB/c male 4 months after the implantation of a 3-methylcholanthrene pellet. It is strongly immunogenic, as evaluated by classical immunization procedures (14) . Tumor development is characterized by a slow growth during 15 days, after which approximately 50% of the tumors begin to regress; by day 40 all regressing tumors have been completely rejected. It was used in passage 6 in vivo.
3) MC-C: This fibrosarcoma arose in a 5-month-old BALBI c male 3 months after the implantation of a 3-methylcholanthrene pellet. It is a strongly immunogenic tumor, its LD50 is about 5XI04 tumor cells, and its spontaneous regression rate is low (14) . It was used in passage 4 in vivo.
Tumor volume was expressed according to the formula of Attia and Weiss (15): vol=O.4 (ab 2 ) , where a and b represent the larger and smaller diameters, respectively.
SVI was calculated as a ratio of survival time in days (mean ± SD) divided by the fraction of mice that died of tumor: SVI is a measure of both the survival time and percentage of mortality. Experimental model.-The primary tumor was implanted sc in the right £lank of BALB/c mice; several days later, a second sc implant of the same tumor was carried out in the left flank (experimental group). Suppression or delay of growth of the second tumor implant was considered as a measure of concomitant resistance. The control group received the "second" implant of tumor cells only in the left flank. At different intervals, the skins from the left flank, with or without macroscopic tumor, of experimental and control mice were removed and fixed immediately in 15% formaldehyde, 5% acetic acid, and 80% methanol. Skin and the underlying primary tumor from the right £lank of experimental mice were processed in the same manner: The tumor was sliced along the largest diameter and embedded with the overlying skin. Serial sections were stained with hematoxylin and eosin, periodic acidSchiff, and reticulum techniques. Mitotic number per HPF was evaluated in thin sections, in well-preserved areas (nonnecrotic) with similar cell densities, while taking into account metaphase and anaphase. In each case, 80 fields were counted. There was good reproducibility from one experiment to another achieved with different passages of the same tumor, so that data from some of the experiments were pooled.
Winn assay.-The antitumor activity of murine spleen cells was investigated with the in vivo Winn test (16) by mixing them with tumor target cells at various lymphocyte:target ratios. The cells were inoculated sc, and tumor growth was evaluated.
In vitro cytotoxicity assay.-Antitumor cytolytic activity was assessed by a modification of the method of Brunner et al. (17) . Spleen cells of normal or tumorbearing mice were mixed with 5 1 Cr labeled tumor target cells at various splenocyte:target cell ratios. The cells were incubated at 37°C during 4 hours in a 5% CO 2 humidified atmosphere. After this period, the cells were centrifuged and radioactivity of the supernatant and residual cells was measured in a gamma counter. The percentage of 5
1
Cr in the supernatant was considered as a measure of antitumor cytotoxic activity of spleen cells. The assays were usually carried out in quadruplicate and in a few cases in triplicate or duplicate.
. Statistical analysis.-X 2 test and Student's t-test were used. Differences were considered significant whenever the P-value was 0.05 or smaller.
RESULTS

Studies of Concomitant Resistance Against CEI
In the experimental group, 20 BALB/c mice were inoculated sc on day -15 with 3XI05 CEI cells (average death latency, 45 days) in the right £lank. On day 0, when the tumor size had reached 600 mm 3 , the mice were challenged with a second sc inoculum of 3X105 CEI cells in the left £lank; simultaneously, a control group of 18 BALB/c mice received 3X105 CEI cells in the left £lank. The growth of CEI as primary tumor in the right £lank of experimental mice can be followed in text-figure 1, which also shows that in the left flank the proliferation of 3XI05 CEI cells (second implant) was significantly retarded as compared with that of the cells No host cells, such as macrophages, lymphocytes, neutrophils, eosinophils, basophils, mast cells, etc., could ever be detected either in the periphery or inside the small tumor affected by concomitant resistance; this result also contrasts with the classical immunologic rejection.
As for the primary graft of CEI tumor growing in the right flank, histologic examination revealed the presence of tumor cells profusely infiltrating the adjacent tissues. As the tumor increased in size, more extensive areas of necrosis, mainly of vascular origin, became evident. No host cell infiltration was observed.
The mitotic number per HPF was determined as a comparative measure of tumor cell proliferation in the left flank of experimental and control mice. As can be seen in table I, while no difference could be detected on day 10, from day 14 onward the difference became statistically significant with values 2.5-3 times greater in the control tumor than in the one undergoing concomitant resistance. To evaluate the putative effect of concomitant resistance against the primary CEI tumor, its mitotic number per HPF was also calculated: It was similar to that of the controls, suggesting that concomi- tant resistance did not affect primary tumor growth. However, this remains to be confirmed, since the "real" control, that is, mice bearing a CEI with the same evolution as that of experimental mice but growing in a host "incapable" of eliciting concomitant resistance, is not available.
A similar experiment was performed in 6 nude BALB/c mice. The results obtained showed that concomitant resistance against CEI could also be induced (text- fig. 2 ). The histologic analysis gave the same results as with euthymic mice, that is: a) no cytotoxic reaction against the second inoculum affected by concomitant resistance and b) no host cells either in the periphery or within the small secondary tumor affected by concomitant resistance.
The lack of participation of immune lymphocytes in the mechanism of concomitant resistance is also suggested by the in vivo Winn test. Spleen cells were obtained from BALB/c mice bearing two CEI implants (of which the second implant failed to grow because of concomitant resistance); they were mixed with IXI0 4 and 3XI03 CEI cells (50:1 and 100:1 splenocyte/CEI cell ratio). The cell mixture was then inoculated sc into syngeneic mice. As shown in table 2, no significant difference could be observed in the experimental group compared with controls receiving CEI cells mixed with normal spleen cells. MC-C, a strongly immunogenic fibrosarcoma induced by 3-methylcholanthrene, was used as the positive control for the Winn assay: 5X10 5 and lXI05 MC-C tumor cells mixed with spleen cells of immune donors were inoculated sc in BALB/c mice, leading to a significantly higher SVI than that of controls inoculated with MC-C mixed with normal donor splenocytes. represents the mean ± SE of 6 mice, except for a (3 mice).
JNCI, VOL. 76, NO_ 6, JUNE 1986 difference between experimental and control mice in the material obtained from the left flank: The scanty tumor cells were located at the inoculation site, between the skin and the muscular layer. At days 8, 11, and 15, the difference became evident: In control mice, abundant neoplastic LB cells infiltrated the muscular layer and the dermis (figs. 3C, 3D) while in experimental mice at the site of the second inoculum there were localized, noninfiltrating, neoplastic LB cells morphologically well preserved and without any sign of necrosis (figs. 3A, 3B). As for the primary LB tumor growing in the right flank, histologic analysis showed the presence of abundant tumor cells infiltrating the adjacent tissues. When the tumor had reached a large volume (3,000 mm 3 ), areas of necrosis were seen. The mitotic number per HPF was calculated in tumor cells from the left flanks of experimental and control groups. As can be seen in table 3, from day 8 onward, the values were significantly higher in the control tumor than in the one affected by concomitant resistance. This difference was significantly increased at days 11 and 15. Mitotic number per HPF was also determined in the primary tumor, to evaluate a putative action of concomitant resistance. In this case, the values were similar to those of the controls, suggesting that concomitant resistance did not affect cell proliferation of the primary tumor even in the latest stages (table 3) .
It was not possible to evaluate the local participation of host lymphocytes in the generation of concomitant resistance with this tumor because of its lymphoid nature. Therefore a similar experiment was carried out in 18 nude BALB/c mice. The results obtained confirmed our previous findings (14) that concomitant resistance against LB could be induced in athymic mice with the same intensity as that observed in immunocompetent mice. The histologic analysis gave the same results as those obtained with euthymic mice; that is, there was no evidence of a classical cytotoxic reaction against the second inoculum undergoing concomitant resistance.
The lack of participation of immune cells in the mechanism of concomitant resistance is also suggested by two additional data. First, spleen cells of LB tumorbearing BALB/c mice undergoing concomitant resistance had no cytotoxic effect against LB cells, as assessed in a 4-hour in vitro assay of 51Cr release (table 4) . Normal BALB/c splenocytes were used as negative control, while splenocytes from AKR mice rejecting LB tumor served as positive control. Second, pretreatment with two doses of 3.6XI06 irradiated LB tumor cells, as the immunization procedure, did not increase the intensity of concomitant resistance generated by LBbearing mice against secondary implants of 10 5 , 5XI05, or 10 6 LB cells (data not shown).
DISCUSSION
Concomitant resistance of a tumor-bearing animal to a second challenge of its own tumor has been described in different experimental systems (18) (19) (20) , but the underlying mechanism remains controversial. In a former paper (14) we were able to demonstrate that concomitant resistance could be generated by murine tumors of
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nondetectable immunogenicity. The histologic data presented herein extends these findings.
First, the capacity of both conventional and nude mice bearing nonimmunogenic spontaneous tumors to inhibit or retard the growth of a second tumor challenge operates without the local participation of host cells: No lymphocytes, macrophages, neutrophils, or other host cells were seen in the periphery or within the secondary CEI implant undergoing concomitant resistance at any of the intervals studied, contrasting with classical immunologic rejection. On the basis of this histologic observation, it is not possible to discard, however, that soluble factors secreted by systemic host cells could mediate this phenomenon. The absence of local participation of host cells could not be directly confirmed with LB tumor because of its lymphoid nature, which made it difficult to differentiate between normal lymphocytes and neoplastic cells. However, the detection of concomitant resistance against LB in nude mice suggests that T -cells are not involved. This is also corroborated by the negative results obtained both with the Winn test and a cytotoxic assay when using as effector cells the splenocytes of mice undergoing concomitant resistance.
Second, our results indicate that concomitant resistance generated by nonimmunogenic tumors operates through a cytostatic mechanism: The second CEI or LB tumor implant that did not grow or that grew at a slower rate remained viable without any sign of necrosis throughout the observation period, until the animals were about to die of the primary tumor. The inhibitory or retarding effect of concomitant resistance was evaluated by determining the mitotic number per HPF, an indirect but comparative measure of tumor cell proliferation. This effect proved to be significantly lower for the second tumor implant than for the controls. This retarding effect was not evident in the first observation period but it became progressively accentuated as the primary tumor developed. This finding is in accordance with our previous observations (14) and that of others (8, 21) , indicating that the degree of concomitant resistance is proportional to the volume of the primary tumor. Such inhibition of cell proliferation rather than b Experimental BALB/c mice were inoculated on day -6 with 10 6 LB cells in the right flank and challenged on day 0 with 10 5 LB cells in the contralateral flank (this second implant did not grow due to concomitant resistance). The assay was carried out on day 8 (14 days after the first implant) when the volume of the primary tumor was 4,800 mm 3 • c P<.Ol between experimental and positive control groups; there was no statistically significant difference between experimental and neIative control groups.
P<.OOl; see footnote c for further information. e AKR mice received the same treatment as BALB/c mice of the experimental group. cell death had been suggested by Gorelik (9) while working with a long-passaged murine tumor of weak immunogenicity and while using a radioisotope technique.
Third, an attempt was made to detect an effect of concomitant resistance on the primary tumor, the one which apparently generates the phenomenon. This attempt was motivated by the following consideration: It is well known that solid tumors grow exponentially up to a certain size, after which the growth curve tends to form a plateau (22) (23) (24) . Could this be due to the same mechanism that retards cell proliferation in the secondary implant undergoing concomitant resistance? Our data do not support this contention, since there was no change in mitotic number per HPF throughout primary tumor growth, even in the last stages of the disease. Our methodology for the detection of mitoses was based on the comparison of microscopic fields of similar cell density, excluding necrotic as well as perinecrotic areas still containing viable cells but already suffering from a failure in vascular supply. This process may explain any divergence with authors who encountered a decrease in the number of mitoses in the last stages of tumor growth while using techniques involving the whole viable cell population (22, 25) . The reason why mito~es were counted in such selected fields was that in the secondary implant the well-preserved state of the arrested cells and the total absence of necrosis suggested that the inhibition of cell proliferation did not have a vascular origin. Therefore, the putative effect of concomitant resistance against the primary tumor had to be tested in comparative areas, excluding all fields affected by a decrease in vascular supply. The effect of concomitant resistance on the secondary tumor and not on the primary tumor cannot be attributed to a fundamental difference originating from an irreversible (genetic?) change of the primary implant during tumor progression since, in our tumor models, the cells used for the secondary implants were routinely obtained from large primary tumors.
Different immunologic and nonimmunologic hypotheses have been proposed to explain concomitant resistance. According to the immunologic hypotheses, the growth of an immunogenic tumor is accompanied by a concomitant immune response during which cytolytic T-cells (26) and, in a lesser degree, macrophages (27, 28) are capable of rejecting a relatively small tumor inoculum. This explanation is not very different from that of conventional immunologic rejection of allogeneic or strongly immunogenic syngeneic tumors, as seen in our tumor controls and as described by others (29, 30) . The reason why the primary tumor escapes immunologic control remains controversial (21) ; it has been successively attributed to blocking serum antibodies (31) , to circulating tumor antigen in excess (32) , and to antigen-antibody complexes (33) . Recently, North and Bursuker (6, 7, 34) have proposed that before cytolytic T-cell-mediated concomitant resistance could be strong enough to destroy the primary tumor it is down regulated by Lyl +2-suppressor T-cells, leaving the host in a specific state of tolerance that is maintained for many days even after tumor excision. Our results would seem to contradict the abundant experimental evidence reviewed by North (26) , which supports the immunologic explanation. However, all this information is based on experiments with strongly immunogenic tumors induced mainly by chemical agents, while our studies have been carried out with spontaneous tumors of nondetectable immunogenicity. Two different mechanisms could be involved, and the possibility exists that a non immunologic component may be present in concomitant resistance generated by both nonimmunogenic and immunogenic tumors; in the case of immunogenic tumors, the nonimmunogenic component would be masked by a second, i.e., immunologic, component.
As for non immunologic explanations of concomitant resistance, basically two hypotheses have been formulated. Ehrlich (35), who originally described this phenomenon at the beginning of the century, believed that the secondary tumor did not grow because of a depletion of essential nutrients by the primary tumor. Moreover, Gorelik (36) and De Wyss (24) postulated that the production of anti proliferative nonspecific substances by tumor-bearing mice could be responsible for the inhibition of both the secondary implant and metastases. De Wyss (24) also suggested that these antiproliferative factors would act against the primary tumor, which data, as mentioned above, our data would not favor. Why such a "factor" could inhibit the proliferation of a small secondary tumor and not that of a large primary tumor is unknown; proliferation could be attributed either to the different structures of the two tumors, the larger one making difficult "physically" the entry of this factor, or to the different ratio between the concentration of tumor cells and that of the putative inhibitor. Other nonimmunologic mechanisms are possible, for instance, either the presence of growth factors with limited negative feedback, which could limit secondary tumor growth but only up to a certain implant dose so that larger tumors would not be inhibited in their growth, or a tumor-induced factor with bivalent effects, one of growth promotion (on the primary tumor) and the other of growth inhibition (on secondary implants), depending on the factor's concentration relative to the number of tumor cells. In this sense, the existence of purified polypeptides with both stimulatory and inhibitory capacity on tumor cell proliferation has been recently reported (37) .
Whatever the explanation, a possible conclusion is that concomitant resistance can be induced by nonimmunogenic as well as immunogenic tumors and that an understanding of the mechanisms involved may eventually contribute to the control of malignant diseases. 
